In this issue:
- Carboplatin + an anthracycline taxane chemotherapy backbone in early TNBC
- Sacituzumab govitecan + pembrolizumab for advanced TNBC
- Trastuzumab deruxtecan for advanced breast cancer
- Real-world post-progression outcomes after CDK4/6 inhibitors
- Concomitant radiation therapy and trastuzumab deruxtecan
- Ten-year survival after postmastectomy chest-wall irradiation
- Impact on women of population-based breast density notification in Australia
- Impact of breast density notification on interval cancer rates
- Pathologic complete response rates to anti-HER2 therapy in HER2+ breast cancer
- Interruption of tamoxifen for pregnancy
Please login below to download this issue (PDF)